{"id":328143,"date":"2026-10-27T12:12:07","date_gmt":"2026-10-27T06:42:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=328143"},"modified":"2026-10-27T12:12:07","modified_gmt":"2026-10-27T06:42:07","slug":"over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/","title":{"rendered":"3 Over-the-Counter Formulations Exporter, Cardiovascular and CNS Brand Leader and Contract Manufacturing Specialist Stocks With a Strong Future Roadmap: Marksans Pharma, Torrent Pharmaceuticals and Innova Captab"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Marksans Pharma, Torrent Pharmaceuticals and Innova Captab: ROE of 12.9% to 25.5% and FY22 to FY26 revenue CAGR of 12.4% to 19.5%. Prices as of 26 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three OTC, specialty brand and contract pharma stocks to watch are Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Their return on equity ranges from 12.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 19.5%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Innova Captab has the fastest revenue growth at 19.5% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>OTC, specialty brand and contract pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Torrent Pharmaceuticals and Innova Captab cover an over-the-counter formulations exporter, a cardiovascular and CNS brand leader and a contract manufacturing specialist.<\/p>\n<p>This list covers three OTC, specialty brand and contract pharma stocks with complete current figures: Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#What_Are_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"What Are OTC, Specialty Brand and Contract Pharma Stocks?\">What Are OTC, Specialty Brand and Contract Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#OTC_Specialty_Brand_and_Contract_Pharma_Stocks_at_a_Glance\" title=\"OTC, Specialty Brand and Contract Pharma Stocks at a Glance\">OTC, Specialty Brand and Contract Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Why_Do_OTC_Specialty_Brand_and_Contract_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do OTC, Specialty Brand and Contract Pharma Stocks Have a Strong Roadmap in India?\">Why Do OTC, Specialty Brand and Contract Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Why_Marksans_Pharma_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"Why Marksans Pharma Features Among These OTC, Specialty Brand and Contract Pharma Stocks\">Why Marksans Pharma Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Why_Torrent_Pharmaceuticals_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"Why Torrent Pharmaceuticals Features Among These OTC, Specialty Brand and Contract Pharma Stocks\">Why Torrent Pharmaceuticals Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Why_Innova_Captab_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"Why Innova Captab Features Among These OTC, Specialty Brand and Contract Pharma Stocks\">Why Innova Captab Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Marksans_Pharma_vs_Torrent_Pharmaceuticals_vs_Innova_Captab_on_Key_Financials\" title=\"Marksans Pharma vs Torrent Pharmaceuticals vs Innova Captab on Key Financials\">Marksans Pharma vs Torrent Pharmaceuticals vs Innova Captab on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Key_Risks_to_Check_Before_Investing_in_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in OTC, Specialty Brand and Contract Pharma Stocks\">Key Risks to Check Before Investing in OTC, Specialty Brand and Contract Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Final_Thoughts_on_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\" title=\"Final Thoughts on OTC, Specialty Brand and Contract Pharma Stocks\">Final Thoughts on OTC, Specialty Brand and Contract Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#What_are_OTC_specialty_brand_and_contract_pharma_stocks\" title=\"What are OTC, specialty brand and contract pharma stocks?\">What are OTC, specialty brand and contract pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Which_OTC_specialty_brand_and_contract_pharma_stocks_are_covered_in_this_list\" title=\"Which OTC, specialty brand and contract pharma stocks are covered in this list?\">Which OTC, specialty brand and contract pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Why_do_OTC_specialty_brand_and_contract_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do OTC, specialty brand and contract pharma stocks have a strong future roadmap in India?\">Why do OTC, specialty brand and contract pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#How_has_Marksans_Pharma_performed_financially\" title=\"How has Marksans Pharma performed financially?\">How has Marksans Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#How_has_Torrent_Pharmaceuticals_performed_financially\" title=\"How has Torrent Pharmaceuticals performed financially?\">How has Torrent Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#How_has_Innova_Captab_performed_financially\" title=\"How has Innova Captab performed financially?\">How has Innova Captab performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#What_risks_should_investors_check_before_buying_OTC_specialty_brand_and_contract_pharma_stocks\" title=\"What risks should investors check before buying OTC, specialty brand and contract pharma stocks?\">What risks should investors check before buying OTC, specialty brand and contract pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and-contract-manufacturing-specialist-stocks-roadmap-apex-list\/#Is_this_list_of_OTC_specialty_brand_and_contract_pharma_stocks_investment_advice\" title=\"Is this list of OTC, specialty brand and contract pharma stocks investment advice?\">Is this list of OTC, specialty brand and contract pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>What Are OTC, Specialty Brand and Contract Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC, specialty brand and contract pharma stocks are listed drug makers that export over-the-counter products, lead in heart and brain therapies and make formulations for other brands. Their earnings depend on launches, plant quality, prescriptions and outsourcing demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"OTC_Specialty_Brand_and_Contract_Pharma_Stocks_at_a_Glance\"><\/span><strong>OTC, Specialty Brand and Contract Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\">Marksans Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">296.65<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,994<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.11<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,550<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">173,079<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">80.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.79<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/innovacap\/innova-captab-ltd-share-price-today\">Innova Captab<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">998.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.32<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Marksans Pharma trades at a P\/E below the industry P\/E, while Torrent Pharmaceuticals and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing OTC, specialty brand and contract pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in OTC, specialty brand and contract pharma stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_OTC_Specialty_Brand_and_Contract_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do OTC, Specialty Brand and Contract Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC, specialty brand and contract pharma stocks have a strong roadmap in India because trusted brands, export demand for self-care products and outsourced manufacturing keep widening the revenue base.<\/p>\n<ul>\n<li><strong>Self-care exports.<\/strong> Over-the-counter products sell across developed markets.<\/li>\n<li><strong>Chronic therapies.<\/strong> Heart and brain brands retain prescribers.<\/li>\n<li><strong>Outsourced work.<\/strong> Other drug brands hire contract makers.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Marksans_Pharma_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>Why Marksans Pharma Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the OTC, specialty brand and contract pharma stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.<\/p>\n<p>The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7.<\/p>\n<p>Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<p><strong>What to watch:<\/strong> Track export growth, new product approvals and plant utilisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Torrent_Pharmaceuticals_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>Why Torrent Pharmaceuticals Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the UK and US formulation exporter shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.<\/p>\n<p>Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<p><strong>What to watch:<\/strong> Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Innova_Captab_Features_Among_These_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>Why Innova Captab Features Among These OTC, Specialty Brand and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.<\/p>\n<p>In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.<\/p>\n<p>Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<p><strong>What to watch:<\/strong> Watch the growth in the branded business and the utilisation of expanded capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_vs_Torrent_Pharmaceuticals_vs_Innova_Captab_on_Key_Financials\"><\/span><strong>Marksans Pharma vs Torrent Pharmaceuticals vs Innova Captab on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three OTC, specialty brand and contract pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,533<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,033<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">420<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,705<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,886<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,138<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">803<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,637<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with OTC, specialty brand and contract pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">626<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">866<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,909<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Innova Captab<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">473<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in OTC, Specialty Brand and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these OTC, specialty brand and contract pharma stocks, the main points are: Long-term UK and US formulation exporter shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory checks.<\/strong> Plant inspections can affect approvals.<\/li>\n<li><strong>Price pressure.<\/strong> Generic prices abroad can fall.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter OTC, specialty brand and contract pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_OTC_Specialty_Brand_and_Contract_Pharma_Stocks\"><\/span><strong>Final Thoughts on OTC, Specialty Brand and Contract Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC, specialty brand and contract pharma stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Torrent Pharmaceuticals and Innova Captab each have a clear plan to grow. Based on the 26 October 2026 close, Marksans Pharma trades at Rs 296.65, Torrent Pharmaceuticals at Rs 4,550 and Innova Captab at Rs 998.2. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these OTC, specialty brand and contract pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track OTC, specialty brand and contract pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_OTC_specialty_brand_and_contract_pharma_stocks\"><\/span><strong>What are OTC, specialty brand and contract pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> OTC, specialty brand and contract pharma stocks are listed drug makers that export over-the-counter products, lead in heart and brain therapies and make formulations for other brands. Their earnings depend on launches, plant quality, prescriptions and outsourcing demand. This list looks at three of them, Marksans Pharma, Torrent Pharmaceuticals and Innova Captab, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_OTC_specialty_brand_and_contract_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which OTC, specialty brand and contract pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Based on the 26 October 2026 close, Marksans Pharma traded at Rs 296.65, Torrent Pharmaceuticals at Rs 4,550 and Innova Captab at Rs 998.2. Their return on equity ranges from 12.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 19.5%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_OTC_specialty_brand_and_contract_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do OTC, specialty brand and contract pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> OTC, specialty brand and contract pharma stocks have a strong roadmap in India because trusted brands, export demand for self-care products and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Self-care exports. Over-the-counter products sell across developed markets. Chronic therapies. Heart and brain brands retain prescribers. Outsourced work. Other drug brands hire contract makers. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Marksans_Pharma_performed_financially\"><\/span><strong>How has Marksans Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Torrent_Pharmaceuticals_performed_financially\"><\/span><strong>How has Torrent Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Innova_Captab_performed_financially\"><\/span><strong>How has Innova Captab performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_OTC_specialty_brand_and_contract_pharma_stocks\"><\/span><strong>What risks should investors check before buying OTC, specialty brand and contract pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying OTC, specialty brand and contract pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_OTC_specialty_brand_and_contract_pharma_stocks_investment_advice\"><\/span><strong>Is this list of OTC, specialty brand and contract pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are OTC, specialty brand and contract pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"OTC, specialty brand and contract pharma stocks are listed drug makers that export over-the-counter products, lead in heart and brain therapies and make formulations for other brands. Their earnings depend on launches, plant quality, prescriptions and outsourcing demand. This list looks at three of them, Marksans Pharma, Torrent Pharmaceuticals and Innova Captab, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which OTC, specialty brand and contract pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Based on the 26 October 2026 close, Marksans Pharma traded at Rs 296.65, Torrent Pharmaceuticals at Rs 4,550 and Innova Captab at Rs 998.2. Their return on equity ranges from 12.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 19.5%.\"}},{\"@type\":\"Question\",\"name\":\"Why do OTC, specialty brand and contract pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"OTC, specialty brand and contract pharma stocks have a strong roadmap in India because trusted brands, export demand for self-care products and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Self-care exports. Over-the-counter products sell across developed markets. Chronic therapies. Heart and brain brands retain prescribers. Outsourced work. Other drug brands hire contract makers. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Marksans Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Torrent Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.\"}},{\"@type\":\"Question\",\"name\":\"How has Innova Captab performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P\/E of 37.2, above the industry P\/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying OTC, specialty brand and contract pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying OTC, specialty brand and contract pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of OTC, specialty brand and contract pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>OTC, Specialty Brand and Contract Pharma Stocks with a strong future roadmap: Marksans Pharma, Torrent Pharmaceuticals and Innova Captab. Compare price, valuation, return on equity and revenue growth as of 26 October 2026.<\/p>\n","protected":false},"author":34,"featured_media":328142,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,16596,5864,9051,16593,16594,13963,16595],"class_list":["post-328143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cardiac-brand-and-outsourced-drug-stocks","tag-innova-captab","tag-marksans-pharma","tag-otc","tag-specialty-brand-and-contract-pharma-stocks","tag-torrent-pharmaceuticals","tag-uk-and-us-formulation-exporter-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["328142"],"rank_math_title":["OTC Formulation, Specialty Brand and Contract Pharma Stocks"],"rank_math_description":["Compare 3 OTC, specialty brand and contract pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 26 Oct 2026."],"rank_math_focus_keyword":["OTC, specialty brand and contract pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-over-the-counter-formulations-exporter-cardiovascular-and-cns-brand-leader-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/328143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=328143"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/328143\/revisions"}],"predecessor-version":[{"id":328144,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/328143\/revisions\/328144"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/328142"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=328143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=328143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=328143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}